RxDoctor Payments Data

Philippe Genereux, MD

Cardiovascular Disease · New York, NYNPI 1114179264

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $976,533 of the $1,267,790 with a category attached, or 77.0%. 35 manufacturers reported payments, led by Edwards Lifesciences at 29.0% of the total. Among cardiovascular disease clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,267,790in general payments, 2019–2025

Across 1,205 payments — averaging $1052.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$368K
  • Opsens Inc.$319K
  • Saranas, Inc.$267K
  • Cardiva Medical, Inc.$217K
  • Cardiovascular Systems Inc.$31K
  • Shockwave Medical, Inc$20K
  • plus $46K from 29 others
$3,166,439in research payments, 2019–2025

Across 315 payments — averaging $10,052 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Edwards Lifesciences$2.8M
  • Abbott$123K
  • Medtronic$66K
  • Saranas, Inc.$51K
  • Boston Scientific$50K
  • Cardiva Medical, Inc.$34K

What the payments were for

  • Consulting fees$976,53377%
  • Speaking & faculty fees$115,3839%
  • Travel & lodging$132,47410%
  • Food & beverage$42,4703%
  • Entertainment$6480%
  • Other$2820%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,267,790 in reported general payments places this provider in the 95th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$274,993
Medicare patients
442
Services billed
980

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other cardiovascular disease in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →